Gastrointestinal Stromal Tumor (GIST) Market is segmented By Product (Marketed Drugs, Phase III Pipeline Drugs), By Drug Category (Tyrosine Kinase Inhibitors, Chemotherap ....
Market Size in USD
CAGR9.6%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 9.6% |
Market Concentration | High |
Major Players | Novartis AG, Pfizer Inc., Bayer AG, Roche Holding AG, Eli Lilly and Company |
The gastrointestinal stromal tumor (GIST) market is estimated to be valued at USD 1.2 Bn in 2024 and is expected to reach USD 2.28 Bn by 2031, growing at a compound annual growth rate (CAGR) of 9.6% from 2024 to 2031. Major factors such as rising incidence of gastrointestinal cancers, increasing adoption of targeted therapies and growing population aware about the available treatment options for GIST cancers will boost the demand.